Wells Fargo & Company Monte Rosa Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 70,162 shares of GLUE stock, worth $471,488. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,162
Previous 22,210
215.9%
Holding current value
$471,488
Previous $117,000
315.38%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding GLUE
# of Institutions
96Shares Held
51MCall Options Held
141KPut Options Held
31.2K-
Nea Management Company, LLC Timonium, MD7.69MShares$51.7 Million3.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.6MShares$44.4 Million0.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$38 Million58.01% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$33 Million0.28% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.35MShares$29.2 Million0.44% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $314M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...